Skip to main content
mRNA Synthesis Raw Material Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2024-2028

mRNA Synthesis Raw Material Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2024-2028

Published: Mar 2024 170 Pages SKU: IRTNTR77779

Market Overview at a Glance

$776.45 Mn
Market Opportunity
4.93%
CAGR
4.34
YoY growth 2023-2024(%)

mRNA Synthesis Raw Material Market Size 2024-2028

The mrna synthesis raw material market size is forecast to increase by USD 776.45 million at a CAGR of 4.93% between 2023 and 2028.

  • The market is experiencing significant growth due to the increasing prevalence of chronic and infectious diseases, which necessitates the development of advanced therapeutics. Collaborations in biotechnology and manufacturing processes related to mRNA synthesis are also driving market expansion. However, the complexity of mRNA synthesis and purification processes poses a challenge to market growth. The intricacy of these processes requires specialized expertise and advanced technology, which can increase production costs. Despite these challenges, the potential benefits of mRNA-based therapies, such as their ability to deliver precise genetic material to target cells, make them an attractive option for treating various diseases. Overall, the market for mRNA synthesis raw materials is expected to grow steadily In the coming years, as researchers and pharmaceutical companies continue to invest in this promising technology.

    • What will be the Size of the mRNA Synthesis Raw Material Market During the Forecast Period?

    mRNA Synthesis Raw Material Market Size

     Request Free Sample

  • The market is experiencing significant growth due to the increasing demand for MRNA technology in various sectors, including mRNA research, mRNA-based vaccines, and therapeutic applications. With the recent success of mRNA vaccines such as those used for COVID-19, government agencies and research institutions have accelerated their investments in this technology. The flexible and durable nature of mRNA makes it an attractive alternative to traditional treatments for chronic diseases, particularly in healthcare professional-administered settings. High-quality raw materials are essential for ensuring the immunogenicity and efficacy of mRNA vaccines and therapeutics. The market is driven by advancements in RNA technology, including enzymatic capping and DNA-to-RNA transcription, which enhance the stability and efficiency of mRNA production.
  • Applications of mRNA technology extend beyond vaccines to include therapeutics for cancer, cardiovascular diseases, tuberculosis, and other infectious diseases.

    • How is this mRNA Synthesis Raw Material Industry segmented and which is the largest segment?

    The mrna synthesis raw material industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

    • Application
      • Vaccine production
      • Therapeutics production
      • Others
    • End-user
      • Biopharmaceutical and pharmaceutical companies
      • CROs and CMOs
      • Academic and research institutions
    • Geography
      • North America
        • US
      • Europe
        • Germany
        • UK
      • Asia
        • China
        • Japan
      • Rest of World (ROW)

      By Application Insights

      • The vaccine production segment is estimated to witness significant growth during the forecast period.

      MRNA synthesis raw materials have become essential components In the production of mRNA-based vaccines and therapeutics, revolutionizing the biopharmaceutical industry. MRNA technology enables rapid development and scalability of vaccines against various infectious diseases, including HIV, tuberculosis, and cancer. Key players, such as Thermo Fisher Scientific Inc., provide high-quality mRNA synthesis reagents and kits to vaccine manufacturers. These materials are indispensable for producing mRNA-1273 and other mRNA vaccines, enabling the synthesis of proteins for patient populations. Capping agents, nucleotide segments, and enzymatic capping are crucial aspects of mRNA synthesis, ensuring improved medical technology through flexible, durable, and immunogenic vaccines and medications.

      Biopharmaceutical and pharmaceutical companies, CROs & CMOs, and research institutions rely on these raw materials for vaccine production and gene-editing therapies. The therapeutics segment, focusing on chronic diseases, benefits from mRNA technology, with healthcare professionals seeking high-quality raw materials for drug discovery and biotechnology companies developing nutraceuticals and diagnostics research. The nucleotide market segment, including nucleotide analogs, plays a significant role in mRNA synthesis, while capping enzymes and DNA templates are vital for therapeutics production. The use of mRNA synthesis raw materials advances medical technology, enabling the production of mRNA vaccines, medications, and gene therapies.

      mRNA Synthesis Raw Material Market Size

      Get a glance at the  mRNA Synthesis Raw Material Industry report of share of various segments Request Free Sample

      The Vaccine production segment was valued at USD 1622.94 million in 2018 and showed a gradual increase during the forecast period.

      Regional Analysis

      • North America is estimated to contribute 34% to the growth of the global market during the forecast period.

      Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

      mRNA Synthesis Raw Material Market Share by Geography

      For more insights on the market share of various regions, Request Free Sample

      The market in North America is experiencing significant growth due to the increasing focus on mRNA-based therapeutics, vaccines, and diagnostics. With numerous leading research institutions and biopharmaceutical companies based in North America, this region is at the forefront of mRNA innovation. The potential of mRNA technology to address various diseases, such as cancer, infectious diseases, and chronic conditions, has attracted substantial investment and research interest. Key factors driving the growth of the market include advancements in RNA technology, government funding initiatives, strategic collaborations, and a favorable regulatory environment. MRNA-based vaccines, such as mRNA-1273 for COVID-19, have demonstrated impressive results, further fueling market growth.

      The demand for high-quality raw materials, including nucleotides, capping agents, and DNA templates, is crucial for mRNA synthesis processes. The therapeutics segment, including gene-editing therapies, also presents significant opportunities. Biopharmaceutical and pharmaceutical companies, CROs & CMOs, and contract service providers are key players In the market. The market is expected to grow further as mRNA technology continues to evolve, offering improved medical treatments and potential alternatives to traditional ones. Key players are investing in research and development, focusing on the production of flexible, durable, and immunogenic mRNA-based medications and vaccines. High-quality raw materials are essential to ensure the success of these endeavors, making the market a critical component of the biotechnology industry.

      Market Dynamics

      Our  researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

      What are the key market drivers leading to the rise In the adoption of mRNA Synthesis Raw Material Industry?

      Growing prevalence of chronic and infectious diseases is the key driver of the market.

    • The market is experiencing significant growth due to the increasing prevalence of chronic and infectious diseases, leading to a heightened demand for innovative treatment modalities. Chronic conditions, such as cancer, cardiovascular diseases, and autoimmune disorders, are becoming more common worldwide. For instance, cancer accounts for nearly one in six global deaths, and cardiovascular diseases cause approximately 17.9 million deaths annually, according to the World Health Organization (WHO). MRNA technology, a key component of RNA-based vaccines and therapeutic applications, is at the forefront of this innovation. Biotech companies, research institutions, and government agencies are investing heavily in mRNA research to develop vaccines and therapeutics for various diseases, including HIV, cancer, and tuberculosis.
    • MRNA-1273, developed by Moderna Therapeutics, is an example of a successful mRNA vaccine that has entered Phase 1 clinical trials for HIV. The market for mRNA synthesis raw materials includes biopharmaceutical and pharmaceutical companies, CROs & CMOs, and contract service providers. These entities require high-quality raw materials, such as capping agents, nucleotide segment, and nucleotide analogs, for the production of mRNA-based vaccines and therapeutics. Enzymatic capping and CleanCap technology are essential In the process of capping and tailing of mRNA molecules. The therapeutics segment, which includes gene-editing therapies and chronic disease treatments, is a significant contributor to the market's growth.
    • Healthcare professionals and patient populations are increasingly seeking flexible, durable, and effective treatments for various conditions. Traditional treatments, such as medications, are being supplemented with improved medical technology, including mRNA-based therapeutics and vaccines. In conclusion, The market is experiencing significant growth due to the increasing demand for innovative treatments for chronic and infectious diseases. MRNA technology is at the forefront of this innovation, with biotech companies, research institutions, and government agencies investing heavily in research and development. The market includes various stakeholders, including biopharmaceutical and pharmaceutical companies, CROs & CMOs, and contract service providers, all requiring high-quality raw materials for the production of mRNA-based vaccines and therapeutics.
    • The therapeutics segment, which includes gene-editing therapies and chronic disease treatments, is a significant contributor to the market's growth.

      • What are the market trends shaping the mRNA Synthesis Raw Material Industry?

      Collaborations in biotechnology and manufacturing processes related to mRNA synthesis is the upcoming market trend.

    • The market is experiencing significant growth due to the increasing research and development in mRNA technology and the production of mRNA-based vaccines and therapeutic applications. Biotech companies, research institutions, and government agencies are investing heavily in this field, leading to the demand for high-quality raw materials such as nucleotides, capping agents, and polymerases. MRNA vaccines, like Moderna's mRNA-1273 for COVID-19 and HIV vaccines, require precise synthesis of mRNA molecules. This has fueled the need for flexible, durable, and immunogenic raw materials that ensure improved medical technology and maintaIn the required immunogenicity. The therapeutics segment, including gene-editing therapies and treatments for chronic diseases, is also driving market growth.
    • Contract service providers (CROs & CMOs) and biopharmaceutical companies are collaborating to produce vaccines and medications using mRNA technology, further increasing demand for raw materials. Additionally, advancements in RNA technology, such as enzymatic capping and CleanCap technology, are enabling the production of high-quality raw materials for the biotechnology industry. Overall, the market dynamics of the market are driven by the continuous innovation in mRNA technology, the demand for high-quality raw materials, and the increasing applications In therapeutics and vaccines.

      • What challenges does the mRNA Synthesis Raw Material Industry face during its growth?

      Complexity of mRNA synthesis and purification processes is a key challenge affecting the industry growth.

    • The market is experiencing intricate complexities due to the advanced processes involved in mRNA technology. MRNA research and development, driven by the creation of mRNA-based vaccines and therapeutic applications, necessitate high-quality raw materials for efficient production. Biopharmaceutical and pharmaceutical companies, research institutions, and CROs & CMOs are key consumers in this market. The synthesis of mRNA involves several steps, such as the enzymatic transcription of DNA templates, post-transcriptional modifications, and purification. Each step requires specialized reagents, enzymes, and purification techniques, increasing production costs. Consequently, manufacturers must invest in advanced technologies and stringent quality control measures to ensure product purity and consistency.
    • The high costs associated with mRNA synthesis raw materials can deter smaller biotech firms and academic institutions from entering the market or expanding their research and development efforts. However, the potential benefits of mRNA technology in vaccine development, gene-editing therapies, and the treatment of chronic diseases such as cancer, cardiovascular diseases, and tuberculosis, make it an attractive area for investment. The market dynamics include the demand for capping agents, nucleotide segment, and nucleotide analogs. Capping and tailing, enzymatic capping, and CleanCap technology are essential In the production of mRNA. Biopharmaceutical companies and contract service providers play a significant role In therapeutics production and drug discovery.
    • The therapeutics segment, including vaccines and medications, is a major application area for mRNA synthesis raw materials. In conclusion, the market faces challenges due to the complex production processes, but the potential benefits and applications make it a vital area for investment and research. The demand for high-quality raw materials, advanced technologies, and stringent quality control measures will continue to drive market growth.

      • Exclusive Customer Landscape

      The mrna synthesis raw material market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the mrna synthesis raw material market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

      mRNA Synthesis Raw Material Market Share by Geography

       Customer Landscape

      Key Companies & Market Insights

      Companies are implementing various strategies, such as strategic alliances, mrna synthesis raw material market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.

      Bayer AG - The company specializes in supplying mRNA synthesis raw materials, including uridine mRNA, for the development of tumor type-specific, off-the-shelf therapies for cancer patients. These advanced treatments are particularly beneficial for those with hard-to-treat, advanced diseases. The mRNA synthesis raw materials enable the production of therapeutic proteins, which can help modulate gene expression and potentially offer effective treatments for various cancer types. The company's commitment to research and development ensures the delivery of high-quality, reliable raw materials to support the scientific community's ongoing efforts to create innovative cancer therapies.

      The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

      • Bayer AG
      • BioNTech SE
      • BOCSCI Inc.
      • CELONIC Group
      • Corden Pharma International GmbH
      • Creative Biolabs
      • CureVac AG
      • F. Hoffmann La Roche Ltd.
      • GlaxoSmithKline Plc
      • HONGENE
      • Jena Bioscience GmbH
      • Lonza Group Ltd.
      • Maravai LifeSciences Holdings Inc.
      • Merck KGaA
      • New England Biolabs Inc.
      • Pfizer Inc.
      • Promega Corp.
      • Samsung Electronics Co. Ltd.
      • Thermo Fisher Scientific Inc.
      • Yeasen Biotechnology Co. Ltd.

      Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

      Research Analyst Overview

      MRNA synthesis is a critical process In the production of mRNA-based therapeutics and vaccines. This technology, which involves the creation of artificial mRNA molecules to introduce new genetic material into cells, has gained significant attention due to its potential applications in various fields, including healthcare and biotechnology. The raw materials market for mRNA synthesis is a crucial component of this emerging industry. These materials include nucleotides, capping agents, and polymerases, among others. The nucleotide segment is a significant contributor to the market, as it provides the building blocks for mRNA synthesis. Nucleotide analogs, in particular, have gained popularity due to their ability to improve the stability and durability of mRNA molecules.

      The demand for high-quality raw materials in mRNA synthesis is driven by the increasing focus on developing effective mRNA-based vaccines and therapeutics. The therapeutics segment, which includes applications for chronic diseases, cancer, and cardiovascular diseases, among others, is expected to experience significant growth In the coming years. The biopharmaceutical and pharmaceutical industries are major consumers of mRNA synthesis raw materials. These companies rely on contract service providers, such as CROs and CMOs, to produce the raw materials and conduct research and development activities. The use of mRNA technology in vaccine production has gained momentum in recent years, with several companies successfully bringing mRNA-based vaccines to market.

      The research institutions and government agencies are also active players In the market. They invest heavily in research and development activities, focusing on improving the immunogenicity of mRNA-based vaccines and therapeutics. The use of enzymatic capping and cleancap technology, for instance, has been instrumental in enhancing the stability and efficacy of mRNA molecules. The market is expected to grow significantly In the coming years, driven by the increasing demand for mRNA-based vaccines and therapeutics. The market is highly competitive, with several biotechnology companies and nutraceutical companies entering the fray. The market dynamics are influenced by various factors, including technological advancements, regulatory frameworks, and market trends.

      The use of mRNA technology in gene-editing therapies is another emerging application that is expected to drive the demand for mRNA synthesis raw materials. The flexibility and durability of mRNA molecules make them an attractive option for gene therapy applications, particularly In the treatment of chronic diseases. In conclusion, the market is a critical component of the emerging mRNA-based therapeutics and vaccines industry. The market is driven by the increasing demand for effective mRNA-based products, particularly In the therapeutics and vaccine production sectors. The use of high-quality raw materials, such as nucleotides, capping agents, and polymerases, is essential for producing effective and stable mRNA molecules.

      The market is highly competitive, with several players, including biopharmaceutical and pharmaceutical companies, research institutions, and government agencies, vying for a share of the growing market.

      Market Scope

      Report Coverage

      Details

      Page number

      170

      Base year

      2023

      Historic period

      		 2018-2022

      Forecast period

      2024-2028

      Growth momentum & CAGR

      Accelerate at a CAGR of 4.93%

      Market growth 2024-2028

      USD 776.45 million

      Market structure

      Fragmented

      YoY growth 2023-2024(%)

      4.34

      Key countries

      US, Germany, UK, China, and Japan

      Competitive landscape

      Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

      Request Free Sample

      What are the Key Data Covered in this mRNA Synthesis Raw Material Market Research and Growth Report?

      • CAGR of the mRNA Synthesis Raw Material industry during the forecast period
      • Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
      • Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
      • Accurate predictions about upcoming growth and trends and changes in consumer behaviour
      • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
      • Thorough analysis of the market’s competitive landscape and detailed information about companies
      • Comprehensive analysis of factors that will challenge the mrna synthesis raw material market growth of industry companies

      We can help! Our analysts can customize this mrna synthesis raw material market research report to meet your requirements.

      Get in touch

       

      1 Executive Summary

      • 1.1 Market overview
        • Exhibit 01: Executive Summary – Chart on Market Overview
        • Exhibit 02: Executive Summary – Data Table on Market Overview
        • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
        • Exhibit 04: Executive Summary – Chart on Market by Geography
        • Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
        • Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user
        • Exhibit 07: Executive Summary – Chart on Incremental Growth
        • Exhibit 08: Executive Summary – Data Table on Incremental Growth
        • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

      2 Market Landscape

      • 2.1 Market ecosystem
        • Exhibit 10: Parent market
        • Exhibit 11: Market Characteristics

      3 Market Sizing

      • 3.1 Market definition
        • Exhibit 12: Offerings of vendors included in the market definition
      • 3.2 Market segment analysis
        • Exhibit 13: Market segments
      • 3.3 Market size 2023
        • 3.4 Market outlook: Forecast for 2023-2028
          • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
          • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
          • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
          • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

        4 Historic Market Size

        • 4.1 Global mRNA synthesis raw material market 2018 - 2022
          • Exhibit 18: Historic Market Size – Data Table on global mrna synthesis raw material market 2018 - 2022 ($ million)
        • 4.2 Application Segment Analysis 2018 - 2022
          • Exhibit 19: Historic Market Size – Application Segment 2018 - 2022 ($ million)
        • 4.3 End-user Segment Analysis 2018 - 2022
          • Exhibit 20: Historic Market Size – End-user Segment 2018 - 2022 ($ million)
        • 4.4 Geography Segment Analysis 2018 - 2022
          • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)
        • 4.5 Country Segment Analysis 2018 - 2022
          • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)

        5 Five Forces Analysis

        • 5.1 Five forces summary
          • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
        • 5.2 Bargaining power of buyers
          • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
        • 5.3 Bargaining power of suppliers
          • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
        • 5.4 Threat of new entrants
          • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
        • 5.5 Threat of substitutes
          • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
        • 5.6 Threat of rivalry
          • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
        • 5.7 Market condition
          • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

        6 Market Segmentation by Application

        • 6.1 Market segments
          • Exhibit 30: Chart on Application - Market share 2023-2028 (%)
          • Exhibit 31: Data Table on Application - Market share 2023-2028 (%)
        • 6.2 Comparison by Application
          • Exhibit 32: Chart on Comparison by Application
          • Exhibit 33: Data Table on Comparison by Application
        • 6.3 Vaccine production - Market size and forecast 2023-2028
          • Exhibit 34: Chart on Vaccine production - Market size and forecast 2023-2028 ($ million)
          • Exhibit 35: Data Table on Vaccine production - Market size and forecast 2023-2028 ($ million)
          • Exhibit 36: Chart on Vaccine production - Year-over-year growth 2023-2028 (%)
          • Exhibit 37: Data Table on Vaccine production - Year-over-year growth 2023-2028 (%)
        • 6.4 Therapeutics production - Market size and forecast 2023-2028
          • Exhibit 38: Chart on Therapeutics production - Market size and forecast 2023-2028 ($ million)
          • Exhibit 39: Data Table on Therapeutics production - Market size and forecast 2023-2028 ($ million)
          • Exhibit 40: Chart on Therapeutics production - Year-over-year growth 2023-2028 (%)
          • Exhibit 41: Data Table on Therapeutics production - Year-over-year growth 2023-2028 (%)
        • 6.5 Others - Market size and forecast 2023-2028
          • Exhibit 42: Chart on Others - Market size and forecast 2023-2028 ($ million)
          • Exhibit 43: Data Table on Others - Market size and forecast 2023-2028 ($ million)
          • Exhibit 44: Chart on Others - Year-over-year growth 2023-2028 (%)
          • Exhibit 45: Data Table on Others - Year-over-year growth 2023-2028 (%)
        • 6.6 Market opportunity by Application
          • Exhibit 46: Market opportunity by Application ($ million)
          • Exhibit 47: Data Table on Market opportunity by Application ($ million)

        7 Market Segmentation by End-user

        • 7.1 Market segments
          • Exhibit 48: Chart on End-user - Market share 2023-2028 (%)
          • Exhibit 49: Data Table on End-user - Market share 2023-2028 (%)
        • 7.2 Comparison by End-user
          • Exhibit 50: Chart on Comparison by End-user
          • Exhibit 51: Data Table on Comparison by End-user
        • 7.3 Biopharmaceutical and pharmaceutical companies - Market size and forecast 2023-2028
          • Exhibit 52: Chart on Biopharmaceutical and pharmaceutical companies - Market size and forecast 2023-2028 ($ million)
          • Exhibit 53: Data Table on Biopharmaceutical and pharmaceutical companies - Market size and forecast 2023-2028 ($ million)
          • Exhibit 54: Chart on Biopharmaceutical and pharmaceutical companies - Year-over-year growth 2023-2028 (%)
          • Exhibit 55: Data Table on Biopharmaceutical and pharmaceutical companies - Year-over-year growth 2023-2028 (%)
        • 7.4 CROs and CMOs - Market size and forecast 2023-2028
          • Exhibit 56: Chart on CROs and CMOs - Market size and forecast 2023-2028 ($ million)
          • Exhibit 57: Data Table on CROs and CMOs - Market size and forecast 2023-2028 ($ million)
          • Exhibit 58: Chart on CROs and CMOs - Year-over-year growth 2023-2028 (%)
          • Exhibit 59: Data Table on CROs and CMOs - Year-over-year growth 2023-2028 (%)
        • 7.5 Academic and research institutions - Market size and forecast 2023-2028
          • Exhibit 60: Chart on Academic and research institutions - Market size and forecast 2023-2028 ($ million)
          • Exhibit 61: Data Table on Academic and research institutions - Market size and forecast 2023-2028 ($ million)
          • Exhibit 62: Chart on Academic and research institutions - Year-over-year growth 2023-2028 (%)
          • Exhibit 63: Data Table on Academic and research institutions - Year-over-year growth 2023-2028 (%)
        • 7.6 Market opportunity by End-user
          • Exhibit 64: Market opportunity by End-user ($ million)
          • Exhibit 65: Data Table on Market opportunity by End-user ($ million)

        8 Customer Landscape

        • 8.1 Customer landscape overview
          • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

        9 Geographic Landscape

        • 9.1 Geographic segmentation
          • Exhibit 67: Chart on Market share by geography 2023-2028 (%)
          • Exhibit 68: Data Table on Market share by geography 2023-2028 (%)
        • 9.2 Geographic comparison
          • Exhibit 69: Chart on Geographic comparison
          • Exhibit 70: Data Table on Geographic comparison
        • 9.3 North America - Market size and forecast 2023-2028
          • Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
          • Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
          • Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
          • Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
        • 9.4 Europe - Market size and forecast 2023-2028
          • Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
          • Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
          • Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
          • Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
        • 9.5 Asia - Market size and forecast 2023-2028
          • Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
          • Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
          • Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
          • Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
        • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
          • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
          • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
          • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
          • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
        • 9.7 US - Market size and forecast 2023-2028
          • Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
          • Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
          • Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
          • Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
        • 9.8 China - Market size and forecast 2023-2028
          • Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ million)
          • Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ million)
          • Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
          • Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
        • 9.9 Germany - Market size and forecast 2023-2028
          • Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
          • Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
          • Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
          • Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
        • 9.10 UK - Market size and forecast 2023-2028
          • Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
          • Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
          • Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
          • Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
        • 9.11 Japan - Market size and forecast 2023-2028
          • Exhibit 103: Chart on Japan - Market size and forecast 2023-2028 ($ million)
          • Exhibit 104: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
          • Exhibit 105: Chart on Japan - Year-over-year growth 2023-2028 (%)
          • Exhibit 106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
        • 9.12 Market opportunity by geography
          • Exhibit 107: Market opportunity by geography ($ million)
          • Exhibit 108: Data Tables on Market opportunity by geography ($ million)

        10 Drivers, Challenges, and Trends

        • 10.1 Market drivers
          • 10.2 Market challenges
            • 10.3 Impact of drivers and challenges
              • Exhibit 109: Impact of drivers and challenges in 2023 and 2028
            • 10.4 Market trends

              11 Vendor Landscape

              • 11.1 Overview
                • 11.2 Vendor landscape
                  • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
                • 11.3 Landscape disruption
                  • Exhibit 111: Overview on factors of disruption
                • 11.4 Industry risks
                  • Exhibit 112: Impact of key risks on business

                12 Vendor Analysis

                • 12.1 Vendors covered
                  • Exhibit 113: Vendors covered
                • 12.2 Market positioning of vendors
                  • Exhibit 114: Matrix on vendor position and classification
                • 12.3 BioNTech SE
                  • Exhibit 115: BioNTech SE - Overview
                  • Exhibit 116: BioNTech SE - Product / Service
                  • Exhibit 117: BioNTech SE - Key offerings
                • 12.4 BOCSCI Inc.
                  • Exhibit 118: BOCSCI Inc. - Overview
                  • Exhibit 119: BOCSCI Inc. - Product / Service
                  • Exhibit 120: BOCSCI Inc. - Key offerings
                • 12.5 Creative Biolabs
                  • Exhibit 121: Creative Biolabs - Overview
                  • Exhibit 122: Creative Biolabs - Product / Service
                  • Exhibit 123: Creative Biolabs - Key offerings
                • 12.6 CureVac AG
                  • Exhibit 124: CureVac AG - Overview
                  • Exhibit 125: CureVac AG - Product / Service
                  • Exhibit 126: CureVac AG - Key offerings
                • 12.7 F. Hoffmann La Roche Ltd.
                  • Exhibit 127: F. Hoffmann La Roche Ltd. - Overview
                  • Exhibit 128: F. Hoffmann La Roche Ltd. - Business segments
                  • Exhibit 129: F. Hoffmann La Roche Ltd. - Key news
                  • Exhibit 130: F. Hoffmann La Roche Ltd. - Key offerings
                  • Exhibit 131: F. Hoffmann La Roche Ltd. - Segment focus
                • 12.8 HONGENE
                  • Exhibit 132: HONGENE - Overview
                  • Exhibit 133: HONGENE - Product / Service
                  • Exhibit 134: HONGENE - Key offerings
                • 12.9 Jena Bioscience GmbH
                  • Exhibit 135: Jena Bioscience GmbH - Overview
                  • Exhibit 136: Jena Bioscience GmbH - Product / Service
                  • Exhibit 137: Jena Bioscience GmbH - Key offerings
                • 12.10 Lonza Group Ltd.
                  • Exhibit 138: Lonza Group Ltd. - Overview
                  • Exhibit 139: Lonza Group Ltd. - Business segments
                  • Exhibit 140: Lonza Group Ltd. - Key news
                  • Exhibit 141: Lonza Group Ltd. - Key offerings
                  • Exhibit 142: Lonza Group Ltd. - Segment focus
                • 12.11 Maravai LifeSciences Holdings Inc.
                  • Exhibit 143: Maravai LifeSciences Holdings Inc. - Overview
                  • Exhibit 144: Maravai LifeSciences Holdings Inc. - Business segments
                  • Exhibit 145: Maravai LifeSciences Holdings Inc. - Key offerings
                  • Exhibit 146: Maravai LifeSciences Holdings Inc. - Segment focus
                • 12.12 Merck KGaA
                  • Exhibit 147: Merck KGaA - Overview
                  • Exhibit 148: Merck KGaA - Business segments
                  • Exhibit 149: Merck KGaA - Key news
                  • Exhibit 150: Merck KGaA - Key offerings
                  • Exhibit 151: Merck KGaA - Segment focus
                • 12.13 New England Biolabs Inc.
                  • Exhibit 152: New England Biolabs Inc. - Overview
                  • Exhibit 153: New England Biolabs Inc. - Product / Service
                  • Exhibit 154: New England Biolabs Inc. - Key news
                  • Exhibit 155: New England Biolabs Inc. - Key offerings
                • 12.14 Pfizer Inc.
                  • Exhibit 156: Pfizer Inc. - Overview
                  • Exhibit 157: Pfizer Inc. - Product / Service
                  • Exhibit 158: Pfizer Inc. - Key news
                  • Exhibit 159: Pfizer Inc. - Key offerings
                • 12.15 Promega Corp.
                  • Exhibit 160: Promega Corp. - Overview
                  • Exhibit 161: Promega Corp. - Product / Service
                  • Exhibit 162: Promega Corp. - Key offerings
                • 12.16 Thermo Fisher Scientific Inc.
                  • Exhibit 163: Thermo Fisher Scientific Inc. - Overview
                  • Exhibit 164: Thermo Fisher Scientific Inc. - Business segments
                  • Exhibit 165: Thermo Fisher Scientific Inc. - Key news
                  • Exhibit 166: Thermo Fisher Scientific Inc. - Key offerings
                  • Exhibit 167: Thermo Fisher Scientific Inc. - Segment focus
                • 12.17 Yeasen Biotechnology Co. Ltd.
                  • Exhibit 168: Yeasen Biotechnology Co. Ltd. - Overview
                  • Exhibit 169: Yeasen Biotechnology Co. Ltd. - Product / Service
                  • Exhibit 170: Yeasen Biotechnology Co. Ltd. - Key offerings

                13 Appendix

                • 13.1 Scope of the report
                  • 13.2 Inclusions and exclusions checklist
                    • Exhibit 171: Inclusions checklist
                    • Exhibit 172: Exclusions checklist
                  • 13.3 Currency conversion rates for US$
                    • Exhibit 173: Currency conversion rates for US$
                  • 13.4 Research methodology
                    • Exhibit 174: Research methodology
                    • Exhibit 175: Validation techniques employed for market sizing
                    • Exhibit 176: Information sources
                  • 13.5 List of abbreviations
                    • Exhibit 177: List of abbreviations

                  Research Methodology

                  Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

                  INFORMATION SOURCES

                  Primary sources

                  • Manufacturers and suppliers
                  • Channel partners
                  • Industry experts
                  • Strategic decision makers

                  Secondary sources

                  • Industry journals and periodicals
                  • Government data
                  • Financial reports of key industry players
                  • Historical data
                  • Press releases

                  DATA ANALYSIS

                  Data Synthesis

                  • Collation of data
                  • Estimation of key figures
                  • Analysis of derived insights

                  Data Validation

                  • Triangulation with data models
                  • Reference against proprietary databases
                  • Corroboration with industry experts

                  REPORT WRITING

                  Qualitative

                  • Market drivers
                  • Market challenges
                  • Market trends
                  • Five forces analysis

                  Quantitative

                  • Market size and forecast
                  • Market segmentation
                  • Geographical insights
                  • Competitive landscape

                  Interested in this report?

                  Get your sample now to see our research methodology and insights!

                  Download Now

                  Frequently Asked Questions

                  mRNA Synthesis Raw Material market growth will increase by $ 776.45 mn during 2024-2028.

                  The mRNA Synthesis Raw Material market is expected to grow at a CAGR of 4.93% during 2024-2028.

                  mRNA Synthesis Raw Material market is segmented by Application( Vaccine production, Therapeutics production, Others) End-user( Biopharmaceutical and pharmaceutical companies, CROs and CMOs, Academic and research institutions)

                  Bayer AG, BioNTech SE, BOCSCI Inc., CELONIC Group, Corden Pharma International GmbH, Creative Biolabs, CureVac AG, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, HONGENE, Jena Bioscience GmbH, Lonza Group Ltd., Maravai LifeSciences Holdings Inc., Merck KGaA, New England Biolabs Inc., Pfizer Inc., Promega Corp., Samsung Electronics Co. Ltd., Thermo Fisher Scientific Inc., Yeasen Biotechnology Co. Ltd. are a few of the key vendors in the mRNA Synthesis Raw Material market.

                  North America will register the highest growth rate of 34% among the other regions. Therefore, the mRNA Synthesis Raw Material market in North America is expected to garner significant business opportunities for the vendors during the forecast period.

                  US, Germany, UK, China, Japan

                  • Growing prevalence of chronic and infectious diseasesThe growing prevalence of chronic and infectious diseases is a significant driver behind the growth of the global mRNA synthesis raw material market. With chronic conditions such as cancer is the driving factor this market.
                  • cardiovascular diseases is the driving factor this market.
                  • and autoimmune disorders becoming increasingly prevalent worldwide is the driving factor this market.
                  • there is a heightened demand for innovative treatment modalities that offer improved efficacy and fewer side effects. For instance is the driving factor this market.
                  • according to the World Health Organization (WHO) is the driving factor this market.
                  • cancer is one of the major causes of death globally is the driving factor this market.
                  • leading to almost one in six deaths is the driving factor this market.
                  • and cardiovascular diseases lead to approximately 17.9 million deaths every year. Additionally is the driving factor this market.
                  • according to WHO is the driving factor this market.
                  • around 10 million people (1.1 million children is the driving factor this market.
                  • 5.6 million men is the driving factor this market.
                  • and 3.3 million women) suffered from tuberculosis globally in 2020. mRNA-based therapies present a promising approach to address these unmet medical needs is the driving factor this market.
                  • offering the potential to target specific disease pathways with precision and customization. Moreover is the driving factor this market.
                  • the rise of infectious diseases is the driving factor this market.
                  • including the ongoing COVID-19 pandemic is the driving factor this market.
                  • has underscored the urgent need for rapid vaccine development and deployment. mRNA vaccines have emerged as a breakthrough technology is the driving factor this market.
                  • enabling the rapid development and production of vaccines against novel pathogens by harnessing the body natural immune response mechanisms. As a result is the driving factor this market.
                  • there is a growing demand for raw materials used in mRNA synthesis is the driving factor this market.
                  • including nucleotides is the driving factor this market.
                  • enzymes is the driving factor this market.
                  • and buffers is the driving factor this market.
                  • to support the development and manufacturing of mRNA-based therapeutics and vaccines. Furthermore is the driving factor this market.
                  • the increasing global burden of disease is the driving factor this market.
                  • coupled with advancements in biotechnology and healthcare innovation is the driving factor this market.
                  • is driving investment in mRNA research and development. Pharmaceutical companies is the driving factor this market.
                  • biotech firms is the driving factor this market.
                  • and academic institutions are actively exploring the potential of mRNA technology to address a wide range of diseases is the driving factor this market.
                  • from cancer and infectious diseases to rare genetic disorders. This growing pipeline of mRNA-based therapies and vaccines is fueling demand for high-quality raw materials to support preclinical studies is the driving factor this market.
                  • clinical trials is the driving factor this market.
                  • and commercial-scale manufacturing. Additionally is the driving factor this market.
                  • as mRNA technology continues to evolve is the driving factor this market.
                  • there is a need for specialized raw materials that offer enhanced performance characteristics to optimize mRNA synthesis processes and improve product quality. Therefore is the driving factor this market.
                  • the growing prevalence of chronic and infectious diseases will drive the growth of the global mRNA synthesis raw material market during the forecast period. is the driving factor this market.

                  The mRNA Synthesis Raw Material market vendors should focus on grabbing business opportunities from the Vaccine production segment as it accounted for the largest market share in the base year.